Recurrent YAP1-MAML2 fusions have been reported in poroma and porocarcinomas, pediatric NF2‐wildtype meningioma, composite and retiform hemangioendothelioma, glioblastoma, nasopharyngeal carcinoma and ovarian cancer cell lines (19–24). This evidence concerns the gene YAP1 and meningioma.